Skip to main content
. Author manuscript; available in PMC: 2023 Mar 20.
Published in final edited form as: Thromb Res. 2021 Sep 20;207:96–98. doi: 10.1016/j.thromres.2021.09.005

Table 1.

Depicting patients who developed erythrocytosis and thromboembolic events.

Thromboembolic event Age (years) Testosterone Hgb. (g/dL), Hct. (%) at diagnosis Months on testosterone at diagnosis Comorbidities
Superficial vein thrombosis in greater saphenous vein 32 Intramuscular Testosterone Cypionate 13.2, 38.8 49 Occurred after reconstructive plastic surgery, obesity
Non-occlusive thrombus in the anterior tibial vein 21 Intramuscular Testosterone Cypionate 14.5, 43.7 36 Tobacco use, recent leg trauma
Ischemic stroke 35 Intramuscular Testosterone Cypionate 14.7, 45.4 207 Dyslipidemia, obesity, tobacco use
Non-occlusive R. peroneal & posterior tibial veins 39 Intramuscular Testosterone Cypionate 17.2, 47.7 168 None
Superficial thrombus in bilateral saphenous veins 22 Intramuscular Testosterone Cypionate 12.2, 35.2 42 Occurred after reconstructive plastic surgery